For the CSS, TSS, and OSS, the Emax of the SGLT-2 inhibitors on the quality of life in HF patients is 3.74%, 4.43%, and 4.84%, respectively, and the ET50 is 2.23 weeks, 4.37 weeks, and 7.15 weeks, respectively. This evidence concerns the gene SLC5A2 and hydrops fetalis.